Vita 34 AG
XETRA:V3V
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
EV/EBIT
Enterprise Value to EBIT (EV/EBIT) ratio compares a company`s total enterprise value to its earnings before interest and taxes. It shows how much investors are paying for each dollar of the company`s earnings, including both equity and debt.
Enterprise Value to EBIT (EV/EBIT) ratio compares a company`s total enterprise value to its earnings before interest and taxes. It shows how much investors are paying for each dollar of the company`s earnings, including both equity and debt.
Valuation Scenarios
If EV/EBIT returns to its Industry Average (16.2), the stock would be worth €-0.58 (113% downside from current price).
| Scenario | EV/EBIT Value | Implied Price | Upside/Downside |
|---|---|---|---|
| Current Multiple | -126.7 | €4.53 |
0%
|
| Industry Average | 16.2 | €-0.58 |
-113%
|
| Country Average | 15.5 | €-0.56 |
-112%
|
Forward EV/EBIT
Today’s price vs future ebit
| Today's Enterprise Value | EBIT | Forward EV/EBIT | ||
|---|---|---|---|---|
|
€85m
|
/ |
Oct 2024
€-579k
|
= |
|
|
€85m
|
/ |
Dec 2024
€-606k
|
= |
|
|
€85m
|
/ |
Dec 2025
€1.5m
|
= |
|
|
€85m
|
/ |
Dec 2026
€3.8m
|
= |
|
|
€85m
|
/ |
Dec 2027
€5.3m
|
= |
|
|
€85m
|
/ |
Dec 2028
€10.5m
|
= |
|
|
€85m
|
/ |
Dec 2029
€10.8m
|
= |
|
|
€85m
|
/ |
Dec 2030
€12m
|
= |
|
Forward EV/EBIT shows whether today’s EV/EBIT still looks high or low once future ebit are taken into account.
Peer Comparison
| Market Cap | EV/EBIT | P/E | ||||
|---|---|---|---|---|---|---|
| DE |
|
Vita 34 AG
XETRA:V3V
|
79m EUR | -126.7 | 30.6 | |
| US |
|
CVS Health Corp
NYSE:CVS
|
99.1B USD | 14.2 | 56 | |
| US |
C
|
Cigna Group
XMUN:CGN
|
69.7B EUR | 10 | 13.5 | |
| US |
|
Cigna Corp
NYSE:CI
|
72.6B USD | 0 | 12.2 | |
| DE |
|
Fresenius Medical Care AG
XMUN:FME
|
23.1B EUR | 16.8 | 23.6 | |
| DE |
|
Fresenius SE & Co KGaA
XETRA:FRE
|
22.7B EUR | 13.7 | 17.9 | |
| US |
|
Quest Diagnostics Inc
NYSE:DGX
|
21.8B USD | 15.8 | 21.4 | |
| US |
|
Laboratory Corporation of America Holdings
NYSE:LH
|
21.7B USD | 17.2 | 24.7 | |
| DE |
F
|
Fresenius Medical Care AG & Co KGaA
XETRA:FME
|
10.8B EUR | 9.9 | 11.1 | |
| US |
|
Guardant Health Inc
NASDAQ:GH
|
11.6B USD | -27.7 | -27.9 | |
| US |
|
DaVita Inc
NYSE:DVA
|
10.4B USD | 9.8 | 13.9 |
Market Distribution
| Min | 0.1 |
| 30th Percentile | 10.6 |
| Median | 15.5 |
| 70th Percentile | 23.1 |
| Max | 672.9 |
Other Multiples
Vita 34 AG
Glance View
Vita 34 AG engages in the collection and storage of umbilical cord blood and stem cells. The company is headquartered in Leipzig, Sachsen and currently employs 124 full-time employees. The company went IPO on 2007-03-27. The firm is involved in the long-term storage and processing of stem cells from human umbilical cord blood. The cells are collected at the child’s birth and can be used later in his or her life for the treatment of many diseases, such as anemia, diabetes, degenerative joint diseases, cancer, neurological deficits after brain injuries, cartilage damages and others. They also allow the growing of whole organs, such as the liver. On average, one out seven individuals, whose cells are stored, receives autologous stem cell transplant by the age of 70. The firm acts as a cord blood bank and is also engaged in research activities in the area of regenerative medicine, including curing the consequences of strokes and heart attacks. The firm operates in Germany, Spain and Denmark.
